NPPA Orders Strict Monitoring of Revised Prices of 137 Anti-Cancer Drugs
The NPPA has directed strict monitoring of revised prices of 137 anti-cancer drugs effective from November 9, 2026. State Drug Controllers must ensure compliance and submit action taken reports by November 16.
NPPA Orders Strict Monitoring of Revised Prices of 137 Anti-Cancer Drugs
CNB WORLD TIMES
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed State Drug Controllers to strictly monitor the implementation of revised prices of 137 non-scheduled anti-cancer drugs under the Trade Margin Rationalisation (TMR) initiative.
The revised prices, notified through a Gazette Order dated 17 October 2026, came into effect on 9 November 2026. The latest revised price lists, based on information submitted by pharmaceutical companies up to 11 November, are available on the NPPA website and the Pharma Sahi Daam app and portal.
The NPPA has directed all manufacturers, retailers, dealers, stockists, hospitals and medical institutions to follow the revised prices. They must also prominently display the updated price lists at their premises and on their websites.
State Drug Controllers Asked to Ensure Compliance
State Drug Controllers (SDCs) have been instructed to closely monitor manufacturers, medicine dealers, hospitals and medical institutions to ensure that patients receive the benefits of the revised Maximum Retail Prices (MRPs).
Any violation, including overcharging, may invite action under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.
Consumers can report complaints related to overcharging, shortages or non-availability of medicines through the Pharma Sahi Daam app or portal. Complaints can also be registered through the NPPA helpline at 1800-111-255 or by email at monitoring-nppa[at]gov[dot]in.
The NPPA has directed all State Drug Controllers to submit their Action Taken Reports (ATRs) by 16 November 2026.
What's Your Reaction?
